Drug Trial Radar · NCT06492915
Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
Aug 13, 2024
Primary completion
Feb 28, 2027
Study completion May 31, 2027
Sponsor
- Lead sponsor
- Chipscreen Biosciences, Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Chiauranib , which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory microenvironment.
Conditions
- Pancreatic Ductal Adenocarcinoma
Interventions
ChiauranibDrug
Chiauranib, 25 mg, 35 mg or 50 mg, oral administration once daily
Albumin-paclitaxel InjectionDrug
Albumin-paclitaxel Injection, 125 mg/m\^2 administered intravenously on Days 1, 8 and 15 of each 28-day cycle
Gemcitabine InjectionDrug
Gemcitabine Injection, 1000 mg/m\^2 administered intravenously on Days 1, 8 and 15 of each 28-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- PFSTime frame: From the first dose to disease progression or end of study, an average of 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.